NCT03640156View on ClinicalTrials.gov

Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Oxytocin

A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.

OTHER

Placebo

A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.

Trial Locations (1)

3000

Katholieke Universiteit Leuven, Leuven

All Listed Sponsors
lead

KU Leuven

OTHER

NCT03640156 - Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin | Biotech Hunter | Biotech Hunter